Tom van Blarcom
Directeur Technique/Scientifique/R&D chez KYVERNA THERAPEUTICS, INC.
Profil
Tom van Blarcom is currently the Senior Vice President & Head-Research at Kyverna Therapeutics, Inc. He previously worked as the Senior Director-Medical at Genentech, Inc., the Executive Director & Head-Protein Engineering at Allogene Therapeutics, Inc., and the Vice President at Horizon Therapeutics, Inc. Dr. van Blarcom completed his undergraduate studies at Universite Paris Est.
Creteil Val De Marne and North Carolina State University.
He holds a doctorate degree from The University of Texas at Austin.
Postes actifs de Tom van Blarcom
| Sociétés | Poste | Début |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Tom van Blarcom
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Corporate Officer/Principal | - |
Formation de Tom van Blarcom
| Universite Paris Est Creteil Val De Marne | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
